These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 37498130

  • 1. Discovery of novel and highly potential inhibitors of glycogen synthase kinase 3-beta (GSK-3β) through structure-based pharmacophore modeling, virtual computational screening, docking and in silico ADMET analysis.
    Benghanem S, Mesli F, Fatima Zohra HA, Nacereddine C, Hadjer C, Abdellatif M.
    J Biomol Struct Dyn; 2024 Sep; 42(14):7091-7106. PubMed ID: 37498130
    [Abstract] [Full Text] [Related]

  • 2. Receptor-based pharmacophore modeling, virtual screening, and molecular docking studies for the discovery of novel GSK-3β inhibitors.
    El Kerdawy AM, Osman AA, Zaater MA.
    J Mol Model; 2019 May 25; 25(6):171. PubMed ID: 31129879
    [Abstract] [Full Text] [Related]

  • 3. Novel hybrid virtual screening protocol based on pharmacophore and molecular docking for discovery of GSK-3β inhibitors.
    Liu X, Yu J, Luo Y, Dong H.
    Chem Biol Drug Des; 2023 Feb 25; 101(2):326-339. PubMed ID: 35762873
    [Abstract] [Full Text] [Related]

  • 4. Identifying potential Alzheimer's disease therapeutics through GSK-3β inhibition: A molecular docking and dynamics approach.
    Mohammadi Y, Emadi R, Maddahi A, Shirdel S, Morowvat MH.
    Comput Biol Chem; 2024 Aug 25; 111():108095. PubMed ID: 38805865
    [Abstract] [Full Text] [Related]

  • 5. Identification of dual kinase inhibitors of CK2 and GSK3β: combined qualitative and quantitative pharmacophore modeling approach.
    Pardhi T, Vasu K.
    J Biomol Struct Dyn; 2018 Jan 25; 36(1):177-194. PubMed ID: 27960601
    [Abstract] [Full Text] [Related]

  • 6. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
    Hu Y, Zhou L, Zhu X, Dai D, Bao Y, Qiu Y.
    J Biomol Struct Dyn; 2019 Jul 25; 37(10):2703-2715. PubMed ID: 30052133
    [Abstract] [Full Text] [Related]

  • 7. Screening of potential drug for Alzheimer's disease: a computational study with GSK-3 β inhibition through virtual screening, docking, and molecular dynamics simulation.
    Elangovan ND, Dhanabalan AK, Gunasekaran K, Kandimalla R, Sankarganesh D.
    J Biomol Struct Dyn; 2021 Nov 25; 39(18):7065-7079. PubMed ID: 32779973
    [Abstract] [Full Text] [Related]

  • 8. In-Silico Screening of Ligand Based Pharmacophore, Database Mining and Molecular Docking on 2, 5-Diaminopyrimidines Azapurines as Potential Inhibitors of Glycogen Synthase Kinase-3β.
    Mishra P, Kesar S, Paliwal SK, Chauhan M, Madan K.
    Cent Nerv Syst Agents Med Chem; 2018 Nov 25; 18(2):150-158. PubMed ID: 29848281
    [Abstract] [Full Text] [Related]

  • 9. The mood stabilizing properties of AF3581, a novel potent GSK-3β inhibitor.
    Capurro V, Lanfranco M, Summa M, Porceddu PF, Ciampoli M, Margaroli N, Durando L, Garrone B, Ombrato R, Tongiani S, Reggiani A.
    Biomed Pharmacother; 2020 Aug 25; 128():110249. PubMed ID: 32470749
    [Abstract] [Full Text] [Related]

  • 10. E-pharmacophore-based virtual screening to identify GSK-3β inhibitors.
    Natarajan P, Priyadarshini V, Pradhan D, Manne M, Swargam S, Kanipakam H, Bhuma V, Amineni U.
    J Recept Signal Transduct Res; 2016 Oct 25; 36(5):445-58. PubMed ID: 27305963
    [Abstract] [Full Text] [Related]

  • 11. Discovery of Novel GSK-3β Inhibitors Using Pharmacophore and Virtual Screening Studies.
    Balakrishnan N, Raj JS, Kandakatla N.
    Interdiscip Sci; 2016 Sep 25; 8(3):303-11. PubMed ID: 26298578
    [Abstract] [Full Text] [Related]

  • 12. Identification of potential PKC inhibitors through pharmacophore designing, 3D-QSAR and molecular dynamics simulations targeting Alzheimer's disease.
    Iqbal S, Anantha Krishnan D, Gunasekaran K.
    J Biomol Struct Dyn; 2018 Nov 25; 36(15):4029-4044. PubMed ID: 29182053
    [Abstract] [Full Text] [Related]

  • 13. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
    Zhang P, Hu HR, Huang ZH, Lei JY, Chu Y, Ye DY.
    Bioorg Med Chem Lett; 2012 Dec 01; 22(23):7232-6. PubMed ID: 23099099
    [Abstract] [Full Text] [Related]

  • 14. Docking and ADMET prediction of few GSK-3 inhibitors divulges 6-bromoindirubin-3-oxime as a potential inhibitor.
    Nisha CM, Kumar A, Vimal A, Bai BM, Pal D, Kumar A.
    J Mol Graph Model; 2016 Apr 01; 65():100-7. PubMed ID: 26967552
    [Abstract] [Full Text] [Related]

  • 15. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
    Darshit BS, Balaji B, Rani P, Ramanathan M.
    J Mol Graph Model; 2014 Sep 01; 53():31-47. PubMed ID: 25064440
    [Abstract] [Full Text] [Related]

  • 16. Prediction of binding affinity of 1,2-diphenyline ketone analogues at adenosine triphosphate binding site of glycogen synthase kinase-3β: a molecular docking and dynamic simulation study.
    Dinakar S, Gurubarath M, Dhananjayan K.
    J Biomol Struct Dyn; 2023 Jul 01; 41(11):4847-4862. PubMed ID: 35543239
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Design, synthesis, antineoplastic activity of new pyrazolo[3,4-d]pyrimidine derivatives as dual CDK2/GSK3β kinase inhibitors; molecular docking study, and ADME prediction.
    Nemr MTM, Elshewy A, Ibrahim ML, El Kerdawy AM, Halim PA.
    Bioorg Chem; 2024 Sep 01; 150():107566. PubMed ID: 38896936
    [Abstract] [Full Text] [Related]

  • 19. Design and Synthesis of Novel Imidazole Derivatives Possessing Triazole Pharmacophore with Potent Anticancer Activity, and In Silico ADMET with GSK-3β Molecular Docking Investigations.
    Al-Blewi F, Shaikh SA, Naqvi A, Aljohani F, Aouad MR, Ihmaid S, Rezki N.
    Int J Mol Sci; 2021 Jan 25; 22(3):. PubMed ID: 33503871
    [Abstract] [Full Text] [Related]

  • 20. Discovery of thiazolidin-4-one analogue as selective GSK-3β inhibitor through structure based virtual screening.
    Choudhary BS, Sukanya, Mehta P, Bach S, Ruchaud S, Robert T, Josselin B, Filipek S, Malik R.
    Bioorg Med Chem Lett; 2021 Nov 15; 52():128375. PubMed ID: 34560262
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.